Semptomatik Remisyon Şizofrenide Fonksiyonel Düzelmeyi ve Yaşam Kalitesini Belirler
Yıl: 2016 Cilt: 53 Sayı: 4 Sayfa Aralığı: 328 - 333 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022
Semptomatik Remisyon Şizofrenide Fonksiyonel Düzelmeyi ve Yaşam Kalitesini Belirler
Öz: Sonuç: Bu çalışma, şizofrenide belirtilerdeki düzelmenin hastanın ha- yatının tüm alanlarında işlevselliğini ve hayat kalitesini yükselttiğini gös- termiştir ki bu bulgu şizofreni tedavisinde amaçlanan fonksiyonel dü- zelmeyi belirleyen en önemli etkenin belirtilerdeki düzelme olduğunu düşündürmektedir
Anahtar Kelime: Konular:
Symptomatic Remission Determines Functional Improvement and Quality of Life in Schizophrenia
Öz: TR), Quality of Life Scale for Schizophrenia Patients (QLS), and Global Assessment of Functioning Scale (GAF). Results: The total and all subscale scores of PANSS and the CGI-S score were significantly lower in the R-Sch group than in the NonR-Sch group, whereas the GAF scores and all subscales of QLS and WHOQOL-BREF-TR were significantly higher. Conclusion: This study demonstrates that improvement in symptoms in schizophrenia patients improves quality and functionality in all areas of life, suggesting that an improvement in symptoms is the most important determinant of functional recovery in the treatment of schizophrenia
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- l. Tarbox SI, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Heinsenn R, McGlashan TH, Woods SW Functional development in clinical high risk youth: Prediction of schizo— phrenia versus other psychotic disorders. Psychiatry Res 20l4; 2l5:52—60. [CrossRef]
- 2. Eren l, Şimşek D, Çalışkan AM. Şizofreni hastalarında yetiyitimi ve belirti şid— detinin yaşam kalitesine etkisi. Düşünen Adam: Psikiyatri ve Nörolojik Bilimler Dergisi 2007; 20:68—78.
- 3. Andreasen NC, Carpenter WT, KaneJM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consen sus. AmJ Psychiatry 2005; I62z44 —449. [CrossRef]
- 4. Fan ><, Henderson DC, Nguyen DD, Cather C, Freudenreich O, Evins AE, Borba C, Goff DC. Posttraumatic stress disorder, cognitive function and qual ity of life in patients with schizophrenia. Psychiatry Res 2008; I59:I40—I46. [CrossRef]
- 5. Priebe S, McCabe R, Junghan U, KallertT, Ruggeri M, Slade M, Reininghaus U. Association between symptoms and quality of life in patients with schizophre nia: pooled analysis of changes over time. Schizophr Res 20l I; I33: 7—2l. [CrossRef]
- 6. Fitzpatrick R, Fletcher A, Gore S, Jones D, Spiegelhalter D, Co>< D. Quality of life measures in health care. I: Applications and issues in assessment. BMJ I992; 305: 074— 077. [CrossRef]
- 7. Keister KJ, Blixen CE. Quality of life and aging] Gerontol Nurs I998; 24:22—28. [CrossRef]
- 8. Karadayi G, Emiroğlu B, Üçok A. Relationship of symptomatic remission with quality of life and functionality in patients with schizophrenia. Compr Psychia try 20I I; 52:70I—707. [CrossRef]
- 9. Ciudad A, Alvarez E, Bobes J, San L, Polavieja P, Gilaberte l. Remission in schizophrenia: results from follow—up I—year observational study Schizophr Res 2009; IO8:2I4—222. [CrossRef]
- |O. Wobrock T, Köhler J, Klein P, Falkai Achieving symptomatic remission in out—patients with schizophrenia—a naturalistic study with quetiapine. Acta Psy— chiatr Scand 2009; I20: I20— 28. [CrossRef]
- I. Bankole A, Cohen Cl, Vahia I, Diwan S, Palekar N, Reyes P, Sapra M, Ramirez PM. Symptomatic remission in multiracial urban population of older adults with schizophrenia. AmJ Geriatr Psychiatry 2008; léz9éé—973. [CrossRef]
- I2. Peuskens J, Trivedi JK, Brecher M, Miller Study Investigators. Long—term symptomatic remission of schizophrenia with once—daily extended release quetiapine fumarate: post—hoc analysis of data from randomized with— drawal, placebo—controlled study Int Clin Psychopharmacol 20l0; 25:l83— l87. [CrossRef]
- I3. Bodén R, Sundström J, Lindström E, Lindström L. Association between symp— tomatic remission and functional outcome in first—episode schizophrenia. mın— Schizophr Res 2009; I07:232—237. [CrossRef]
- Bobes J. Ciudad A. Alvarez E. San L. Polavieja P. Gilaberte l. Recovery from schizophrenia: results from I—year follow—up observational study of patients ih symptomatic remission. Schizophr Res 2009; I5:58—66. [CrossRef]
- Wunderink L. Nienhuis FJ. Sytema S. Wiersma D. Predictive validity of pro posed remission criteria in first—episode schizophrenic patients responding to antipsychotics. Schizophr Bull 2007; 33:792—796. [CrossRef]
- Leucht S. Lasser R. The concepts of remission and recovery in schizophrenia. Pharmacopsychiatry 2006; 39: l— I70. [CrossRef]
- Lambert M. Schimmelmann BG. Naber D. Schacht A. Karow A. Wagner T. Czekalla J. Prediction of remission as combination of symptomatic and functional remission and adequate subjective well—being in 2960 patients with schizophreniaJ Clin Psychiatry 2006; 67: 690— 697. [CrossRef]
- Van OsJ. Drukker M. CampoJ. MeijerJ. Bal< M. Delespaul Validation of remission criteria for schizophrenia. Am Psychiatry 2006; I63:2000—2002. [CrossRef]
- Helldih L. KaneJM. Karilampi U. NorlahderT. ArcherT Remission in prognosis of functional outcome: new dimension in the treatment of patients with psychotic disorders. Schizophr Res 2007; 93: 60— 68. [CrossRef]
- Guy Clinical global impression scale. The ECDEU Assessment Manual for Psychopharmacology—Revised I976; 76:2 8—222.
- Kay SR. Elszbeih A. Opfer LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull I987; I3:26 —276. [CrossRef]
- Endicott J. Spitzer RL. EIeiss JL. Cohen J. The global assessment scale. pro— cedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry l976; 33:766—77 l. [CrossRef]
- Eser E. Eidaner H. Fidaner C. Eser SY. Elbi H. Göker. E. WHOQOL—BREE TR: suitable instrument for the assessment of quality of life for use in the health care settings in Turkey Qual Life Res I999; 8:647.
- Heinrichs DV/. Hanlon TE. Carpenter Jr WT The quality of life scale. Schizo phr Bull I984; I0:388—398. [CrossRef]
- Milev P. Ho BC. Arndt S. Andreasen NC. Predictive values of heurocognition and negative symptoms on functional outcome ih schizophrenia: longitudinal first—episode study with 7—year follow—up. AmJ Psychiatry 2005; 62:495—506. [CrossRef]
- Brissos S. Dias VV. Balanza—Martinez V. Carita Al. Figueira ML. Symptomatic remission in schizophrenia patients: relationship with social functioning. quality of life. ahd neurocognitive performance. Schizophr Res 20l l; l29:l33—l36. [CrossRef]
- Bruce ML. Takeuchi DT. Leaf PJ. Poverty and psychiatric status: longitudinal evidence from the New Haven Epidemiologic Catchmeht Area Study. Arch Geh Psychiatry l99 l; 48:470—474. [CrossRef]
- Stephens T. Dulberg C. Joubert N. La santé mentale de la population ca— nadienne: une analyse exhaustive. Maladies Chroniques au Canada I999; 20: I3 I— 40.
- Huber G. Gross G. Schüttler R. long—term follow—up study of schizophrenia: psychiatric course of illness and prognosis. Acta Psychiatr Scand I975; 52:49— 57. [CrossRef]
- Koivumaa—Honkaneh HT. Viihamâki H. Honkanen R. Tanskaneh A. Antikaihen R. Niskanen L. Jââskelâinen J. Lehtonen J. Correlates of life satisfaction among psychiatric patients. Acta Psychiatr Scand I996; 94:372—378. [CrossRef]
- Cardoso CS. Caiaffa WT. Bandeira M. Siqueira AL. Abreu MNS. FonsecaJOP Factors associated with low quality of life in schizophrenia. Cadernos de Saude Publica 2005; 2|: I338—I340. [CrossRef]
- HuppertJD. Weiss KA. Lim R. Pratt S. Smith. TE. Quality of life in schizophre— nia: contributions of anxiety and depression. Schizophr Res 200 I; 80. [CrossRef]
- Kokaçya et al. Symptomatic Remission in Schizophrenia McEvoyJP. MeyerJM. Goff DC. Nasrallah HA. Davis SM. Sullivan L. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Res 2005; 80: 9—32. [CrossRef]
- Kugo A. Terada S. Ishizu H. Takeda T. Sato S. Habara. Quality of life for patients with schizophrenia in Japanese psychiatric hospital. Psychiatry Res 2006; I44:49—56. [CrossRef]
- Browne S. Clarke M. Gervin M. Waddington JL. Larkin C. O'Callaghan E. De terminants of quality of life at first presentation with schizophrenia BrJ Psy— chiatry 2000; l76: 73— 76. [CrossRef]
- Fitzgerald PB. Williams CL. Corteling N. Filia SL. Brewer K. Adams A. De Castella ARA. Rolfe T. Davey Kull<arni J. Subject and observer—rated quality of life ih schizophrenia. Acta Psychiatr Scand 200 l; l03:387—392. [CrossRef]
- Ritsner M. Kurs R. Quality of life outcomes in mental illness: schizophrenia. mood and anxiety disorders. Expert Rev Pharmacoecon Outcomes Res 2003; 3: 89—I99. [CrossRef]
- Packer S. Husted J. Cohen S. Tomlinson G. Psychopathology ahd quality of life in schizophrenia.J Psychiatry Neurosci I997; 22:23 I—234.
- Eack SM. Newhill CE. Psychiatric symptoms ahd quality of life in schizophrenia: meta—analysis. Schizophr Bull 2007; 33: 225— 237. [CrossRef]
- Thorup A. Petersen L. Jeppeseh P. Nordentoft M. The quality of life among first—episode psychotic patients in the opus trial. Schizophr Res 20 0; 6:27 34. [CrossRef]
- NarvaezJM. Twamley EVV. McKibbin CL. Heaton RK. Patterson TL. Subjective and objective quality of life in schizophrenia. Schizophr Res 2008; 98:20 —208. [CrossRef]
- Karow A. Moritz S. Lambert M. Schoder S. Krausz M. PANSS syndromes and quality of life in schizophrenia. Psychopathology 2005; 38:320—326. [CrossRef]
- Galletly CA. Clark CR. McEarlahe AC. Weber DL. Relationships between changes in symptom ratings. neuropsychological test performance ahd quality of life in schizophrenic patients treated with clozapine. Psychiatry Res I997; 72: 66. [CrossRef]
- Ruggeri M. Nose M. Bonetto C. Cristofalo D. Lasalvia A. Salvi G. Stefani B. Malchiodi E. Tahsella M. Changes and predictors of change ih objective and subjective quality of life Multiwave follow—up study in community psychiatric practice. BrJ Psychiatry 2005; I87: 2l—I30. [CrossRef]
- Lewis S. Escalona P. Keith Phenomenology of schizophrenia. Sadock B. Sadock and Ruiz P. editors.Kaplan ahd Sadocks Comprehensive Textbook of Psychiatry in. 9th edition Philadelphia: Lippihcott. Williams Wilkins;2009. p. l443—l447.
- Kao YC. Liu YP Chou MK. Cheng TH. Subjective quality of life in patients with chronic schizophrenia: relationships between psychosocial and clinical charac— teristics. Compr Psychiatry 20| I; 52: l7 80. [CrossRef]
- Jung HY. Hwang SSH. Yi JS. Kim Y. Kim YS. Clinician—rated functioning and patient—rated quality of life in schizophrenia: Implications of their correspondence for psychopathology and side effects. Prog Neuropsychopharmacol Biol Psychiatry 20 0; 34:225—230. [CrossRef]
- Harvey PD. Velligah DI. Bellack AS. Performance—based measures of function— al skills: usefulness in clinical treatment studies. Schizophr Bull 2007; 33:| I38— I48. [CrossRef]
- Becchi A. Rucci P. Placentino A. Neri G. de Girolamo G. Quality of life ih pa tients with schizophrenia—comparison of self—report and proxy assessments. Soc Psychiatr Epidemiol 2004; 39:397—40I [CrossRef]
- Voruganti L. Heslegrave R. Awad AG. Seeman MV Quality of life measure— ment in schizophrenia: reconciling the quest for subjectivity with the question of reliability Psychol Med I998; 28: 65—I72. [CrossRef]
| APA | kokaçya m, VIRIT O, ÇÖPOĞLU Ü, SAVAŞ H, ARI M, BAHÇECİ B (2016). Semptomatik Remisyon Şizofrenide Fonksiyonel Düzelmeyi ve Yaşam Kalitesini Belirler. , 328 - 333. |
| Chicago | kokaçya mehmet hanifi,VIRIT Osman,ÇÖPOĞLU Ümit Sertan,SAVAŞ Haluk,ARI Mustafa,BAHÇECİ Bülent Semptomatik Remisyon Şizofrenide Fonksiyonel Düzelmeyi ve Yaşam Kalitesini Belirler. (2016): 328 - 333. |
| MLA | kokaçya mehmet hanifi,VIRIT Osman,ÇÖPOĞLU Ümit Sertan,SAVAŞ Haluk,ARI Mustafa,BAHÇECİ Bülent Semptomatik Remisyon Şizofrenide Fonksiyonel Düzelmeyi ve Yaşam Kalitesini Belirler. , 2016, ss.328 - 333. |
| AMA | kokaçya m,VIRIT O,ÇÖPOĞLU Ü,SAVAŞ H,ARI M,BAHÇECİ B Semptomatik Remisyon Şizofrenide Fonksiyonel Düzelmeyi ve Yaşam Kalitesini Belirler. . 2016; 328 - 333. |
| Vancouver | kokaçya m,VIRIT O,ÇÖPOĞLU Ü,SAVAŞ H,ARI M,BAHÇECİ B Semptomatik Remisyon Şizofrenide Fonksiyonel Düzelmeyi ve Yaşam Kalitesini Belirler. . 2016; 328 - 333. |
| IEEE | kokaçya m,VIRIT O,ÇÖPOĞLU Ü,SAVAŞ H,ARI M,BAHÇECİ B "Semptomatik Remisyon Şizofrenide Fonksiyonel Düzelmeyi ve Yaşam Kalitesini Belirler." , ss.328 - 333, 2016. |
| ISNAD | kokaçya, mehmet hanifi vd. "Semptomatik Remisyon Şizofrenide Fonksiyonel Düzelmeyi ve Yaşam Kalitesini Belirler". (2016), 328-333. |
| APA | kokaçya m, VIRIT O, ÇÖPOĞLU Ü, SAVAŞ H, ARI M, BAHÇECİ B (2016). Semptomatik Remisyon Şizofrenide Fonksiyonel Düzelmeyi ve Yaşam Kalitesini Belirler. Nöropsikiyatri Arşivi, 53(4), 328 - 333. |
| Chicago | kokaçya mehmet hanifi,VIRIT Osman,ÇÖPOĞLU Ümit Sertan,SAVAŞ Haluk,ARI Mustafa,BAHÇECİ Bülent Semptomatik Remisyon Şizofrenide Fonksiyonel Düzelmeyi ve Yaşam Kalitesini Belirler. Nöropsikiyatri Arşivi 53, no.4 (2016): 328 - 333. |
| MLA | kokaçya mehmet hanifi,VIRIT Osman,ÇÖPOĞLU Ümit Sertan,SAVAŞ Haluk,ARI Mustafa,BAHÇECİ Bülent Semptomatik Remisyon Şizofrenide Fonksiyonel Düzelmeyi ve Yaşam Kalitesini Belirler. Nöropsikiyatri Arşivi, vol.53, no.4, 2016, ss.328 - 333. |
| AMA | kokaçya m,VIRIT O,ÇÖPOĞLU Ü,SAVAŞ H,ARI M,BAHÇECİ B Semptomatik Remisyon Şizofrenide Fonksiyonel Düzelmeyi ve Yaşam Kalitesini Belirler. Nöropsikiyatri Arşivi. 2016; 53(4): 328 - 333. |
| Vancouver | kokaçya m,VIRIT O,ÇÖPOĞLU Ü,SAVAŞ H,ARI M,BAHÇECİ B Semptomatik Remisyon Şizofrenide Fonksiyonel Düzelmeyi ve Yaşam Kalitesini Belirler. Nöropsikiyatri Arşivi. 2016; 53(4): 328 - 333. |
| IEEE | kokaçya m,VIRIT O,ÇÖPOĞLU Ü,SAVAŞ H,ARI M,BAHÇECİ B "Semptomatik Remisyon Şizofrenide Fonksiyonel Düzelmeyi ve Yaşam Kalitesini Belirler." Nöropsikiyatri Arşivi, 53, ss.328 - 333, 2016. |
| ISNAD | kokaçya, mehmet hanifi vd. "Semptomatik Remisyon Şizofrenide Fonksiyonel Düzelmeyi ve Yaşam Kalitesini Belirler". Nöropsikiyatri Arşivi 53/4 (2016), 328-333. |
